Member Info for ForFXSake

Soupdragon, sorry I must have missed all that detail about costs, timescales and content in the last RNS:

" In particular, the net proceeds will be used to fund a focused programme of additional pre-clinical studies to reinforce areas identified during ongoing out-licensing discussions and due diligence with both large pharmaceutical and speciality pharma partners, and to further advance the NXP002 programme."

Interesting that you say that now though. Wasn't your response to same point last friday more like:

"Show me another company that has given a list of pre-clinical trials, timelines and costs."

LT, Just to add, I respect your opinion as I do everyone elses on this board. Everyone is and should be entitled to express their thoughts on where things are heading, positive or negative.

I'm not (as Littlened likes to fantasise) a paid troll. My critical stance comes from the fact that I'm old enough and have been shafted enough times to know not to believe everything I read or hear...unless there is evidence to back it up.

LT, with regards to a) they are not really investors. They do not hold long enough to even be required to log a TR1.

If these 'investors' are able to forward sell discounted shares at higher prices before the true effect of the dilution is felt (as described by spodulike) then it is always a winning trade for them. They make instant profit and do not have to hold at all. They are not investing, they are trading and the discount makes it low risk.

The only good thing about it is that the company is highly likely to get some funds to fight another day. However, this is always at massive dilution to the existing shareholders and the benefit of that all depends on the capabilities of the board and how they intend to use that money, which brings us to point b).

Ok, critical funds have been earmarked for further studies but we have no idea what they are, how long they will take, what they cost nor what tangible benefit there is at the end. Yes, we are told it is to increase chances of getting a deal...but with who!? If we are at the due diligence stage then why is there still absolutely no evidence or proof that shareholders can see that a partner has said "if your shareholders pay for this then here's the deal"? There is nothing visible and I'm tired of hearing the old 'confidentiality' BS excuse.

If a partnership is really that close then why will they not even reveal their interest? It seems to me that if there really is an interested party then the shareholders are being held over a barrel where we are being forced to take all the risk with nothing in return. It feels more like crowdfunding than investing! What kind of partner will they be going forward?

The thing that makes it worse is that we are now being told that there are multiple partners! Shouldn't they actually be competing with each other?

Have you worked out that valuation yet Littlened?

LT, I did try that for a while, early on after 2020 up until around the time of Brindley when phase 1 had a target date but it seems to have become a bottomless pit.

There is no transparency. Just a stream of piecemeal, sequential projects which just pop up one after the other, to apparently satisfy some 'partner' who never commits support and never reveals anything about their identity. Tell me honestly, were you not expecting them to have all they needed to conclude partnership talks once FDA ODD was in the bag?

Yet here we are, more money required to fund work which is still not detailed or quantified. Still no definite date. We could be having this same conversation this time next year...when the money starts to run out again.

Oh poor littlened getting all upset about opinions that don't align with his own! 😭

Why don't you try and work out how to use filter button again?

I'm afraid I won't be selling up and moving on quietly at this shambolic price. What I have left isn't worth that much anyway, after all the years of failure to deliver value.

As a long term shareholder who has deep regrets about investing here, I think it is important to share what I know with others so that they can make informed decisions before jumping in head first rather than just being influenced by the rampy guff spouted by the P&D merchants.

18p. Bid now.

Sterling work!

My own guess is that the price will rattle around in the .2's until they have something positive to report of partnership progress. How long that will be is anyone's guess.

We know that further clinical work is required to tick due diligence boxes but we don't know details such as how many, the nature of them or timescales involved. If AI simulation on existing data is good enough to complete this work and that doesn't involve having to wait for donors in order to treat new lung slices then it should be alot quicker otherwise it could be months

No. I think it's probably the same 'investors' ldoing the same thing as always happens for every Nuformix placing since Brindley took the reigns...short termers in for a discounted price to benefit from a quick profit before the shares are released. If it was any other way they'd have to release a TR1.

I reckon those who are patient enough and who still believe may get a brief opportunity to buy below the discounted price tomorrow, unless there is a spike in buying.

Welcome to Nuformix

"There seem to be persistent sellers despite the fundamentals.Would be partners ?"

What! Logic please?

The fundamentals are not great. We don't make a profit and have nothing to sell yet. We still have limited funds for any kind of development, even after the placing. We are also not even benefitting from any kind of milestones from the pointless sale of NXP001 to Oxilio yet.

The fact that there are no TR1's and that the price is above .2p suggests to me that this is some kind of short selling of held shares before the recipients hand them back or last minute offloading of existing shares at best price possible before the new shares are issued tomorrow (i.e there is no difference to ownership or holding to report.

So my guess is spodulike is correct.

Just Dan you say? Is he part time or full time?

Interesting. I was aware from previous RNS that Maddy & Julian had expressed that they were not going to take a salary until things turned around. I thought I read here that Gooding had done the same.

However, it seems that someone is still being remunerated to the tune of £90k per annum, according to the Annual report.

Have they all gone back on the payroll now?

Go back to school Littlened, lunchtimes over and the grown-ups are talking

I thought they weren't taking salaries at this time

Why has the company not revealed exactly what trial work is required and what the expected timelines and costs are?Everything is being done one baby step at a time. There is just no urgency.

My guess is it will take months or even longer to complete the initial work required.

The problem is...we don't have partners yet and only 1 million in cash to take us forwards to phase 1, which we should have entered years ago before the Brindley regime came crashing down. Alot of time has passed since then and you can bet our competitors have not been idle. It is a concern as we only have a part time board.

The question now is how long will it take before they start the clinical trial work that is needed to satisfy any minimum due dilligence and how long will it take to complete and publish the results. No chance of a partner until then.

We have no idea of timelines. Meanwhile there will be alot of impatient P&D merchants who will be itching to get out if they dont see their 2% very soon. I bet they were expecting a quick profit.

If those shares are being sold by one source then there should surely be a TR1 incoming.

Who is John Farthing?

Dumpers are keeping up the pressure though.

Eager to get their 2%

If NXP002 was something that AZ could use then why would they not have picked it up already for the peanuts it is currently worth? This is especially the case since the Oliparib based NXP004 patents were secured, as they could easily fall into a more serious competitors hands and maybe cause a future threat if Nuformix were to bought out.

They cannot be interested otherwise they would have already done it.

Rough AI overview of NXP004 for those that are not familiar:

"NXP004 is a Nuformix oncology program developing novel, patented co-crystal forms of the PARP inhibitor olaparib (Lynparza®). It aims to improve the drug's bioavailability and performance compared to the standard crystalline form. A key US patent (12012386) for these co-crystals was granted in June 2024, strengthening the IP position.

Key Details about NXP004

Objective: To create "bio-better" formulations of olaparib with enhanced performance.

Status: Preclinical development, with lead co-crystals identified and patented.

Goal: The company aims to out-license NXP004 to partners, potentially extending patent protection for olaparib-based therapies until 2040/2041.

Context: Nuformix is developing this to improve upon the blockbuster drug used for BRCA-mutated cancers. "